Pathophysiology of vascular disease in diabetes: effects of gliclazide

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Pharmacology

Background:

• Diabetes mellitus is a significant risk factor for macrovascular complications, including coronary heart disease and peripheral vascular disease.
• These complications are two to four times more prevalent in individuals with diabetes, leading to increased morbidity, mortality, and healthcare expenses.
• The development of macrovascular disease in diabetes is a complex process involving endothelial injury, lipid accumulation, platelet activation, lipoprotein alterations, and impaired coagulation/fibrinolysis.

Purpose of the Study:

• To review the evidence for gliclazide's effects on platelet function and fibrinolysis.
• To evaluate gliclazide's potential benefits beyond glycemic control in managing cardiovascular complications of diabetes.
• To provide recommendations for future research on gliclazide's vascular actions.

Main Methods:

• Literature review of studies investigating gliclazide's impact on platelet aggregation and fibrinolytic activity.
• Analysis of existing data on the relationship between gliclazide, glycemic control, and cardiovascular outcomes.
• Synthesis of evidence regarding the multifactorial pathogenesis of diabetic macrovascular disease.

Main Results:

• Gliclazide, a sulfonylurea, has demonstrated potential actions on platelet function and fibrinolysis.
• These effects may contribute to mitigating the accelerated macrovascular disease seen in diabetes.
• The review consolidates evidence supporting gliclazide's pleiotropic effects.

Conclusions:

• Gliclazide may possess beneficial effects on platelet function and fibrinolysis, in addition to its glucose-lowering properties.
• These vascular actions could be important in addressing the high cardiovascular risk associated with diabetes mellitus.
• Further research is recommended to fully elucidate the clinical significance of gliclazide's non-glycemic effects in diabetic patients.